The UC Irvine Medical Center has been named one of the sites for a novel national study on amyotrophic lateral sclerosis (ALS). Dr. Tahseen Mozaffar, director of the UCI MDA-ALS Research & Clinical Center, will lead the local effort to collect blood and tissue samples from ALS patients. Knowledge generated from study of these samples will speed the development of biomarkers for the diagnosis and monitoring of this chronic, fatal neuromuscular disease. Study leaders from the ALS Therapy Development Institute also believe the data will help researchers worldwide develop effective therapeutics.
UCI chosen as site for nationwide ALS study
The UC Irvine Medical Center has been named one of the sites for a novel national study on amyotrophic lateral…
August 19, 2008